Explore our Resources
Access a curated collection of materials designed to provide insights into our capabilities and expertise across the drug development and manufacturing lifecycle.
Resources
Industry Perspective
Building Better Combination Products by Engaging Device Development Earlier
What this article covers: Device development is not a downstream packaging decision. For injectable combination products, the delivery system can influence usability, dose accuracy, patient safety, manufacturability, regulatory strategy, and commercial readiness….
Industry Perspective
The Rise of the Multi-Modality CDMO: Why Clients Need More Than Capacity
What this article covers: Available capacity can start a conversation, but it cannot carry a complex program to market on its own. Pharma and biopharma companies also need quality, regulatory credibility, technical…
Industry Perspective
OneSource goes for multi-modality to build a global pharma platform
Neeraj Sharma, CEO & Managing Director, OneSource Specialty Pharma Published on Business India Source: OneSource goes for multi-modality to build a global pharma platform OneSource Specialty Pharma Ltd is a new name…
Industry Perspective
AI Reality Check: CFOs Highlight the Biggest Challenges for Mid-Sized Organizations
Anurag Bhagania, CFO, OneSource Specialty Pharma Published on Financial Express CFO Source: AI Reality Check: CFOs Highlight the Biggest Challenges for Mid-Sized Organizations The finance leaders suggest that while AI promises significant…
Whitepaper
Beyond the Molecule: Human Factors Engineering as the Competitive Edge in Drug-Device Combination Products
The molecule isn’t the differentiator anymore. The device is. What this whitepaper covers: How an integrated CDMO turns device usability into commercial advantage for self-administered drug-device combination products. Whitepaper Abstract: For a…
Industry Perspective
Cyber Risk is now a financial risk: Why pharma boards can’t look away
Anurag Bhagania, CFO, OneSource Specialty Pharma Published on ET Edge Insights Source: Cyber Risk is now a financial risk: Why pharma boards can’t look away – ET Edge Insights Cyber risk is…
Whitepaper
Lyophilization by Design: Engineering Stability, Speed, and Scale into the Next Generation of Parenteral Products
What this whitepaper covers: Why lyophilization has become a defining constraint in modern biologics development — and how a QbD-led, integrated approach transforms cycle design into a scalable, regulatory-ready system. Whitepaper Abstract:…
Industry Perspective
The quiet revolution in how we take our medicine
The quiet revolution in how we take our medicine Ravi Kumar, Global Head of Injectables & Corporate Strategy, Portfolio and SPO Published on Money Control, 05 Jun 2026 Three out of four…
Whitepaper
Bioavailability by Design: Lipid Softgel Technology as a Commercial Rescue Path for Poorly Soluble, Low-Bioavailability Molecules
Solubility is broken. The pipeline proves it. What this whitepaper covers: Why solubility failure is the defining challenge of modern oral drug development — and how self-emulsifying softgel technology (SEDDS/SMEDDS/SNEDDS) unlocks bioavailability…